COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention

References

• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet. Respiratory Medicine. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Disease WC. WHO COVID-19 update. 2020 13 April.
   Google Scholar
• Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–98.
   PubMed Web of Science ®Google Scholar
• Coronavirus WN. Situation report–22. World Health Organization. 2019. [Cited 2021 Jan 01]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf
   Google Scholar
• Iqubal A, Syed MA, Najmi AK, et al. Ameliorative effect of nerolidol on cyclophosphamide-induced gonadal toxicity in Swiss Albino mice: biochemical-, histological- and immunohistochemical-based evidences. Andrologia. 2020;52(4):e13535.
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). 2020.
   Google Scholar
• Iqubal A, Syed MA, Haque MM, et al. Effect of nerolidol on cyclophosphamide-induced bone marrow and hematologic toxicity in Swiss albino mice. 2020.
   Google Scholar
• Zheng -Y-Y, Ma Y-T, Zhang J-Y, et al. COVID-19 and the cardiovascular system. 2020;17(5):259–260.
   Google Scholar
• Iqubal A, Iqubal MK, Sharma S, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision. Life Sciences. 2019;218:112–131.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242.
   PubMed Web of Science ®Google Scholar
• Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-538.
   Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. 2020.
   Google Scholar
• Luo W, Li Y-X, Jiang L-J, et al. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci. 2020;41(8):531–543.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 2020.
   Google Scholar
• Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
   PubMed Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA cardiology. 2020.
   Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. 2020.
   Google Scholar
• Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj. 2020;368:m1091.
   Google Scholar
• Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Progress in cardiovascular diseases. 2020.
   Google Scholar
• Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75(18):2352-2371.
   Web of Science ®Google Scholar
• Aggarwal G, Cheruiyot I, Aggarwal S, et al. Association of cardiovascular disease with coronavirus disease 2019 (covid-19) severity: a meta-analysis. Current Problems in Cardiology. 2020;45(8):100617.
   Google Scholar
• Santoso A, Pranata R, Wibowo A, et al. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am J Emerg Med. 2020. DOI:https://doi.org/10.1016/j.ajem.2020.04.052.
   Google Scholar
• CDC. COVID-19 CaCOoAPHw. 2020 Jun 15.
   Google Scholar
• CDC. Key updates for week 23, ending June 6, 2020. Jun 15 2020
   Google Scholar
• Centers for Disease Control and Prevention. COVID-NET: COVID-19-associated hospitalization surveillance network, 2020 Jun 15.
   Google Scholar
• Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012–2022.
   PubMed Web of Science ®Google Scholar
• Rao GH. Global syndemic of metabolic diseases: editorial comments. 2019;1(1):02–04. J Diabetes Clin Res.
   Google Scholar
• Abbatecola A, Antonelli-Incalzi R. COVID-19 spiraling of frailty in older Italian patients. J Nutr Health Aging. 2020;1–3. https://doi.org/10.1007/s12603-019-1308-5
   Google Scholar
• Rate C-F Onder G, Rezza G, Brusaferro S characteristics of patients dying in relation to COVID-19 in Italy. JAMA Published online March. 2020;23.
   Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;1–8:2020.
   Google Scholar
• Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41(19):1821–1829.
   PubMed Web of Science ®Google Scholar
• Epicenter C. Epidemiology for public health. 2020 Jun 15.
   Google Scholar
• Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. 2020.
   Google Scholar
• Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res. 2020;7(1):1–10.
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature. 2001;413(6857):732–738.
   PubMed Web of Science ®Google Scholar
• Seth RB, Sun L, Ea C-K, et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3. Cell. 2005;122(5):669–682.
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu H, Li S, et al. MAVS-MKK7-JNK2 defines a novel apoptotic signaling pathway during viral infection. 2014; 10(3):e1004020.
   Google Scholar
• Zhang W, Gong J, Yang H, et al. The mitochondrial protein mavs stabilizes p53 to suppress tumorigenesis. Cell Reports. 2020;30(3):725–738. e4.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang S, Li F, et al. NLRX1 attenuates apoptosis and inflammatory responses in myocardial ischemia by inhibiting MAVS-dependent NLRP3 inflammasome activation. Molecular Immunology. 2016;76:90–97.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang X, Tong W, et al. Umbelliferone alleviates lipopolysaccharide-induced inflammatory responses in acute lung injury by down-regulating TLR4/MyD88/NF-κB signaling. Inflammation. 2019;42(2):440–448.
   PubMed Web of Science ®Google Scholar
• Iqubal A, Sharma S, Najmi AK, et al. Nerolidol ameliorates cyclophosphamide-induced oxidative stress, neuroinflammation and cognitive dysfunction: plausible role of Nrf2 and NF-κB. Life Sciences. 2019;236:116867.
   PubMed Web of Science ®Google Scholar
• Iqubal A, Ahmed M, Ahmad S, et al. Environmental neurotoxic pollutants. 2020:1–24.
   Google Scholar
• Iqubal A, Syed MA, Najmi AK, et al. Nanostructured lipid‐loaded nerolidol ameliorate cyclophosphamide‐induced neuroinflammation and cognitive dysfunction: molecular and cell biology/neuroinflammation. Alzheimer's Dement. 2020;16:e037013.
   Google Scholar
• Colliva A, Braga L, Giacca M, et al. Endothelial cell–cardiomyocyte crosstalk in heart development and disease. J Physiol. 2020;598(14):2923–2939.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610.
   PubMed Web of Science ®Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418.
   PubMed Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Cardiac injury in patients with corona virus disease 2019. JAMA Cardiol. 2020.
   Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Zheng -Y-Y, Ma Y-T, Zhang J-Y, et al. COVID-19 and the cardiovascular system. Nature Reviews. Cardiology. 2020;17(5):259–260.
   PubMed Web of Science ®Google Scholar
• Inciardi RM, Solomon SD, Ridker PM, et al. Coronavirus 2019 disease (COVID-19), systemic inflammation, and cardiovascular disease. Journal of the American Heart Association. 2020;9(16):e017756.
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7(1):1–12.
   Google Scholar
• Antonio GE, Wong K, Hui DS, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003;228(3):810–815.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. 2020:105949.
   Google Scholar
• Linsell L, Bell J. Effect of hydroxychloroquine in hospitalized patients with COVID-19-preliminary report. 2020.
   Google Scholar
• Mahase EJBBMJ. Covid-19: hydroxychloroquine was ineffective as postexposure prophylaxis, study finds. 2020; 369.
   Google Scholar
• Abd-Elsalam S, Esmail ES, Khalaf M, et al. Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. The American Journal of Tropical Medicine and Hygiene. 2020;103(4):1635–1639.
   PubMed Web of Science ®Google Scholar
• Lane JCE, Weaver J, Kostka K, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. 2020, 20054551.
   Google Scholar
• Zhai P, Ding Y, Wu X, et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020;55(5):105955.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
   Web of Science ®Google Scholar
• Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). 2020.
   Google Scholar
• Monteleone G, Sarzi-Puttini PC Ardizzone S. Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol. 2020;2(5):e255-e256.
   PubMedGoogle Scholar
• Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406–1407.
   PubMed Web of Science ®Google Scholar
• Yu Y, Xu D, Fu S, et al. Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study. Crit Care. 2020;24(1):1–10.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, et al. risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. [Internet]; 2020 [cited 2020 Mar 21]. Online ahead of print; 1807:934.
   Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020.
   Google Scholar
• Dolle J, Grami S, Adule R, et al. Characteristics and outcomes of COVID-19 patients in New York city’s public hospital system. 2020.
   Google Scholar
• Karmen-Tuohy S, Carlucci PM, Zervou FN, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. 2020.
   Google Scholar
• Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. The Journal of Allergy and Clinical Immunology. 2020;146(2):307–314. e4.
   PubMed Web of Science ®Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–1581.
   PubMed Web of Science ®Google Scholar
• Myers LC, Parodi SM, Escobar GJ, et al. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. 2020.
   Google Scholar
• Emmi G, Bettiol A, Mattioli I, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. 2020:102575.
   Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. 2020.
   Google Scholar
• Iaccarino G, Borghi C, Cicero AF, et al. Renin-angiotensin system inhibition in cardiovascular patients at the time of COVID19: much ado for nothing? A statement of activity from the directors of the board and the scientific directors of the Italian society of hypertension. 2020:1–4.
   Google Scholar
• Hypertension ISo. A statement from the international society of hypertension on COVID-19. International Society of Hypertension Edinburgh; 2020.
   Google Scholar
• Krahn A, Bewick S, Chow C, et al. Guidance from the CCS COVID-19 rapid response team. 2020.
   Google Scholar
• Bavishi C, Maddox TM, Messerli F. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. 2020.
   Google Scholar
• Flacco ME, Martellucci CA, Bravi F, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart (British Cardiac Society). 2020;106(19):1519–1524.
   PubMed Web of Science ®Google Scholar
• Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews. Cardiology. 2020;17(9):543–558.
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. 2020.
   Google Scholar
• Iqubal A, Sharma S, Sharma K, et al. Intranasally administered pitavastatin ameliorates pentylenetetrazol-induced neuroinflammation, oxidative stress and cognitive dysfunction. Life Sciences. 2018;211:172–181.
   PubMed Web of Science ®Google Scholar
• Song SL, Hays SB, Panton CE, et al. Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: a preliminary study. Pathogens. 2020;9(9):759.
   Google Scholar
• Butt JH, Gerds TA, Schou M, et al. Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. BMJ Open. 2020;10(12):e044421.
   PubMed Web of Science ®Google Scholar
• Castiglione V, Chiriacò M, Emdin M, et al. Statin therapy in COVID-19 infection. 2020.
   Google Scholar
• Li H. Sodium–glucose cotransporter 2 inhibitors: a drug with antidiabetic and cardioprotective properties. 2020.
   Google Scholar
• McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. The New England Journal of Medicine. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Gupta K, Kunal SJH, Lung. SGLT-2 inhibitors as cardioprotective agents in COVID-19. 2020.
   Google Scholar
• Cure E, Mcjd C, Research MSC, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes & Metabolic Syndrome. Diabetes Metab Syndr. 2020;14(4):349-350.
   Google Scholar
• Dashora U, Patel DC, Gregory R, et al. Association of British Clinical Diabetologists (ABCD) and diabetes UK joint position statement and recommendations on the use of sodium‐glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (updated october 2020). 2020:e14458.
   Google Scholar
• Li Y, Zhou W, Yang L, et al. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. 2020:104833.
   Google Scholar
• Deng Q, Hu B, Zhang Y, et al. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. 2020.
   Google Scholar
• Genetics C-HGIJEJoH. The COVID-19 host genetics initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. 2020;28(6):715-718.
   Google Scholar
• Jiang F, Yang J, Zhang Y, et al. Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat Rev Cardiol. 2014;11(7):413.
   Google Scholar
• Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822–828.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116.
   PubMed Web of Science ®Google Scholar
• Iqubal A, Haque SE, Sharma S, et al. Clinical updates on drug-induced cardiotoxicity. Int J Pharm Sci res. 2018;9:16–26.
   Google Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. 2020.
   Google Scholar
• Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610.
   PubMed Web of Science ®Google Scholar
• Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension (Dallas, Tex. 1979). 2004;43(5):970–976.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Vardeny O, Michel T, et al. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. The New England Journal of Medicine. 2020;382(17):1653–1659.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. J Card Fail. 2020;26(5):370.
   Google Scholar
• De Simone GJESC. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020;13.
   Google Scholar
• Chinese Society of Cardiology EBJZxxgbzz. Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19. 2020;48:E014.
   Google Scholar
• De Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. 2020.
   Google Scholar
• Mancia G, Rea F, Ludergnani M, et al. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. 2020.
   Google Scholar
• Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. 2020.
   Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. 2020.
   Google Scholar
• Esposito S, Tagliabue C, Bosis S, et al. Levofloxacin for the treatment of mycoplasma pneumoniae-associated meningoencephalitis in childhood. International Journal of Antimicrobial Agents. 2011;37(5):472–475.
   PubMed Web of Science ®Google Scholar
• Aromolaran AS, Srivastava U, Alí A, et al. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. PloS One. 2018;13(12):e0208321.
   PubMed Web of Science ®Google Scholar
• Hartman O, Kovanen PT, Lehtonen J, et al. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. European Heart Journal. Cardiovascular Pharmacotherapy. 2017;3(2):92–97.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Y, Zhang S. Cardiovascular impairment in COVID-19: learning from current options for cardiovascular anti-inflammatory therapy. Front Cardiovasc Med. 2020;7:78.
   Google Scholar
• Wong C, Lam C, Wu A, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical and Experimental Immunology. 2004;136(1):95–103.
   PubMed Web of Science ®Google Scholar
• Shiraishi M, Shintani Y, Shintani Y, et al. Alternatively activated macrophages determine repair of the infarcted adult murine heart. The Journal of Clinical Investigation. 2016;126(6):2151–2166.
   PubMed Web of Science ®Google Scholar
• Ngai JC, Ko FW, Ng SS, et al. The long‐term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology (Carlton, Vic.). 2010;15(3):543–550.
   PubMed Web of Science ®Google Scholar
• Batawi S, Tarazan N, Al-Raddadi R, et al. Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health Qual Life Outcomes. 2019;17(1):1–7.
   Google Scholar
• Shah B, Modi P, Sagar SRJLS In silico studies on therapeutic agents for COVID-19: drug repurposing approach. 2020:117652.
   Google Scholar
• Iqubal MK, Chaudhuri A, Iqubal A, et al. Targeted delivery of natural bioactives and lipid-nanocargos against signaling pathways involved in skin cancer. 2020.
   Google Scholar
• Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. 2020.
   Google Scholar
• Chen F, Hao Y, Zhang Z, et al. An urgent call for raising the scientific rigorousness of clinical trials on COVID-19. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(3):301.
   Google Scholar
• Iqubal A, Iqubal MK, Khan A, et al. Gene therapy, a novel therapeutic tool for neurological disorders: current progress, challenges and future prospective. Current Gene Therapy. 2020;20(3):184–194.
   PubMed Web of Science ®Google Scholar
• Iqubal A, Rahman SO, Ahmed M, et al. current quest in natural bioactive compounds for alzheimer’s disease: multi-targeted-designed-ligand based approach with preclinical and clinical based evidence. 2020.
   Google Scholar
• Iqubal MK, Saleem S, Iqubal A, et al. Natural, synthetic and their combinatorial nanocarriers based drug delivery system in the treatment paradigm for wound healing via dermal targeting. Current Pharmaceutical Design. 2020;26(36):4551–4568.
   PubMed Web of Science ®Google Scholar